3.84 USD
+0.13 (+3.5%)
3.84 USD
0 (0%)
ORGO gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 525 industry peers in the Biotechnology industry. ORGO has an average financial health and profitability rating. ORGO is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
- ORGO had positive earnings in the past year.
- In the past year ORGO has reported a negative cash flow from operations.
- ORGO had positive earnings in 4 of the past 5 years.
- In the past 5 years ORGO always reported a positive cash flow from operatings.
1.2 Ratios
- Looking at the Return On Assets, with a value of -2.63%, ORGO belongs to the top of the industry, outperforming 87.43% of the companies in the same industry.
- With an excellent Return On Equity value of -3.47%, ORGO belongs to the best of the industry, outperforming 89.14% of the companies in the same industry.
- Looking at the Return On Invested Capital, with a value of 0.16%, ORGO belongs to the top of the industry, outperforming 88.76% of the companies in the same industry.
- ORGO had an Average Return On Invested Capital over the past 3 years of 3.79%. This is significantly below the industry average of 18.07%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.63% | ||
| ROE | -3.47% | ||
| ROIC | 0.16% |
ROA(3y)1.45%
ROA(5y)6.32%
ROE(3y)2.46%
ROE(5y)11.67%
ROIC(3y)3.79%
ROIC(5y)7.32%
1.3 Margins
- With an excellent Operating Margin value of 0.18%, ORGO belongs to the best of the industry, outperforming 88.76% of the companies in the same industry.
- ORGO's Operating Margin has declined in the last couple of years.
- ORGO has a Gross Margin of 74.49%. This is amongst the best in the industry. ORGO outperforms 83.43% of its industry peers.
- In the last couple of years the Gross Margin of ORGO has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 0.18% | ||
| PM (TTM) | N/A | ||
| GM | 74.49% |
OM growth 3Y-34.07%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.17%
GM growth 5Y1.4%
2. Health
2.1 Basic Checks
- ORGO has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
- Compared to 1 year ago, ORGO has less shares outstanding
- The number of shares outstanding for ORGO has been increased compared to 5 years ago.
- Compared to 1 year ago, ORGO has an improved debt to assets ratio.
2.2 Solvency
- An Altman-Z score of 3.56 indicates that ORGO is not in any danger for bankruptcy at the moment.
- ORGO's Altman-Z score of 3.56 is fine compared to the rest of the industry. ORGO outperforms 70.48% of its industry peers.
- ORGO has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
- ORGO has a Debt to Equity ratio of 0.01. This is comparable to the rest of the industry: ORGO outperforms 46.86% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 3.56 |
ROIC/WACC0.02
WACC9.17%
2.3 Liquidity
- ORGO has a Current Ratio of 3.32. This indicates that ORGO is financially healthy and has no problem in meeting its short term obligations.
- ORGO's Current ratio of 3.32 is on the low side compared to the rest of the industry. ORGO is outperformed by 60.19% of its industry peers.
- ORGO has a Quick Ratio of 2.88. This indicates that ORGO is financially healthy and has no problem in meeting its short term obligations.
- ORGO has a Quick ratio of 2.88. This is in the lower half of the industry: ORGO underperforms 63.62% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.32 | ||
| Quick Ratio | 2.88 |
3. Growth
3.1 Past
- ORGO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -90.91%.
- Measured over the past years, ORGO shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -37.90% on average per year.
- ORGO shows a small growth in Revenue. In the last year, the Revenue has grown by 2.24%.
- Measured over the past years, ORGO shows a quite strong growth in Revenue. The Revenue has been growing by 13.05% on average per year.
EPS 1Y (TTM)-90.91%
EPS 3Y-37.9%
EPS 5YN/A
EPS Q2Q%66.67%
Revenue 1Y (TTM)2.24%
Revenue growth 3Y0.98%
Revenue growth 5Y13.05%
Sales Q2Q%30.98%
3.2 Future
- ORGO is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 29.27% yearly.
- The Revenue is expected to grow by 8.70% on average over the next years. This is quite good.
EPS Next Y-58%
EPS Next 2Y-6.73%
EPS Next 3Y29.27%
EPS Next 5YN/A
Revenue Next Year9.76%
Revenue Next 2Y8.03%
Revenue Next 3Y8.7%
Revenue Next 5YN/A
3.3 Evolution
- The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 384.00, ORGO can be considered very expensive at the moment.
- Based on the Price/Earnings ratio, ORGO is valued cheaper than 88.95% of the companies in the same industry.
- The average S&P500 Price/Earnings ratio is at 27.32. ORGO is valued rather expensively when compared to this.
- With a Price/Forward Earnings ratio of 25.96, ORGO can be considered very expensive at the moment.
- Compared to the rest of the industry, the Price/Forward Earnings ratio of ORGO indicates a rather cheap valuation: ORGO is cheaper than 92.38% of the companies listed in the same industry.
- The average S&P500 Price/Forward Earnings ratio is at 24.30. ORGO is around the same levels.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 384 | ||
| Fwd PE | 25.96 |
4.2 Price Multiples
- ORGO's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. ORGO is cheaper than 94.10% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 21.55 |
4.3 Compensation for Growth
- The decent profitability rating of ORGO may justify a higher PE ratio.
- A more expensive valuation may be justified as ORGO's earnings are expected to grow with 29.27% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-6.73%
EPS Next 3Y29.27%
5. Dividend
5.1 Amount
- ORGO does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
3.84
+0.13 (+3.5%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2025-11-06/amc
Earnings (Next)02-25 2026-02-25/amc
Inst Owners54.62%
Inst Owner Change1.57%
Ins Owners31.34%
Ins Owner Change-0.43%
Market Cap487.33M
Revenue(TTM)465.22M
Net Income(TTM)-13.39M
Analysts85
Price Target8.67 (125.78%)
Short Float %19.28%
Short Ratio6.22
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)47.19%
Min EPS beat(2)-73%
Max EPS beat(2)167.38%
EPS beat(4)2
Avg EPS beat(4)147.99%
Min EPS beat(4)-73%
Max EPS beat(4)570.59%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)3.03%
Min Revenue beat(2)-4.23%
Max Revenue beat(2)10.3%
Revenue beat(4)2
Avg Revenue beat(4)3.25%
Min Revenue beat(4)-6.36%
Max Revenue beat(4)13.3%
Revenue beat(8)5
Avg Revenue beat(8)2.23%
Revenue beat(12)6
Avg Revenue beat(12)1.36%
Revenue beat(16)7
Avg Revenue beat(16)0.62%
PT rev (1m)0%
PT rev (3m)6.25%
EPS NQ rev (1m)0%
EPS NQ rev (3m)35.48%
EPS NY rev (1m)0%
EPS NY rev (3m)216.67%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)6.21%
Revenue NY rev (1m)0%
Revenue NY rev (3m)5.49%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 384 | ||
| Fwd PE | 25.96 | ||
| P/S | 1.05 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.26 | ||
| P/tB | 1.4 | ||
| EV/EBITDA | 21.55 |
EPS(TTM)0.01
EY0.26%
EPS(NY)0.15
Fwd EY3.85%
FCF(TTM)-0.41
FCFYN/A
OCF(TTM)-0.31
OCFYN/A
SpS3.67
BVpS3.04
TBVpS2.74
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0.83
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.63% | ||
| ROE | -3.47% | ||
| ROCE | 0.2% | ||
| ROIC | 0.16% | ||
| ROICexc | 0.19% | ||
| ROICexgc | 0.21% | ||
| OM | 0.18% | ||
| PM (TTM) | N/A | ||
| GM | 74.49% | ||
| FCFM | N/A |
ROA(3y)1.45%
ROA(5y)6.32%
ROE(3y)2.46%
ROE(5y)11.67%
ROIC(3y)3.79%
ROIC(5y)7.32%
ROICexc(3y)5.35%
ROICexc(5y)10.84%
ROICexgc(3y)6.4%
ROICexgc(5y)14.92%
ROCE(3y)4.79%
ROCE(5y)9.27%
ROICexgc growth 3Y-38.4%
ROICexgc growth 5YN/A
ROICexc growth 3Y-36.47%
ROICexc growth 5YN/A
OM growth 3Y-34.07%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.17%
GM growth 5Y1.4%
F-Score2
Asset Turnover0.91
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0.11 | ||
| Cap/Depr | 70.73% | ||
| Cap/Sales | 2.76% | ||
| Interest Coverage | 0.99 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.32 | ||
| Quick Ratio | 2.88 | ||
| Altman-Z | 3.56 |
F-Score2
WACC9.17%
ROIC/WACC0.02
Cap/Depr(3y)177.81%
Cap/Depr(5y)208.05%
Cap/Sales(3y)5.07%
Cap/Sales(5y)5.42%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-90.91%
EPS 3Y-37.9%
EPS 5YN/A
EPS Q2Q%66.67%
EPS Next Y-58%
EPS Next 2Y-6.73%
EPS Next 3Y29.27%
EPS Next 5YN/A
Revenue 1Y (TTM)2.24%
Revenue growth 3Y0.98%
Revenue growth 5Y13.05%
Sales Q2Q%30.98%
Revenue Next Year9.76%
Revenue Next 2Y8.03%
Revenue Next 3Y8.7%
Revenue Next 5YN/A
EBIT growth 1Y-91.44%
EBIT growth 3Y-33.42%
EBIT growth 5YN/A
EBIT Next Year563.55%
EBIT Next 3Y112.83%
EBIT Next 5YN/A
FCF growth 1Y-1334.78%
FCF growth 3Y-48.6%
FCF growth 5YN/A
OCF growth 1Y-238.05%
OCF growth 3Y-38.8%
OCF growth 5YN/A
ORGANOGENESIS HOLDINGS INC / ORGO FAQ
Can you provide the ChartMill fundamental rating for ORGANOGENESIS HOLDINGS INC?
ChartMill assigns a fundamental rating of 5 / 10 to ORGO.
Can you provide the valuation status for ORGANOGENESIS HOLDINGS INC?
ChartMill assigns a valuation rating of 4 / 10 to ORGANOGENESIS HOLDINGS INC (ORGO). This can be considered as Fairly Valued.
What is the profitability of ORGO stock?
ORGANOGENESIS HOLDINGS INC (ORGO) has a profitability rating of 6 / 10.
What is the financial health of ORGANOGENESIS HOLDINGS INC (ORGO) stock?
The financial health rating of ORGANOGENESIS HOLDINGS INC (ORGO) is 5 / 10.